Etoposide in recurrent childhood Langerhans' cell histiocytosis: an Italian cooperative study.
Eighteen evaluable children with recurrent Langerhans' cell histiocytosis (LCH) which was resistant to standard therapy, were treated with etoposide (VP 16-213), 200 mg/m2/day for 3 days every 3 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses were demonstrated in 15 patients (83.3%). Only one of the 12 children achieving a complete remission has relapsed. No dose-limiting major toxicities were registered. Although etoposide might be an effective treatment in recurrent LCH which needs a chemotherapeutic approach, it is emphasized that this drug must be used carefully.
Ceci
A
A
Second Department of Pediatrics, University of Bari, Italy.
de Terlizzi
M
M
Colella
R
R
Balducci
D
D
Toma
M G
MG
Zurlo
M G
MG
Macchia
P
P
Mancini
A
A
Indolfi
P
P
Locurto
M
M
D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D054747:Histiocytic Sarcoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D007801:Langerhans Cells / Q000473:pathology*; D008297:Male; D012008:Recurrence
D005047:Etoposide